Statistics clinical trial design

Many of the important statistical aspects of clinical trials design are dealt with in detail in Chapter 6 of this volume (Nigel Baber and John Sweatman) and so here only specific statistical aspects are discussed. 

Three comments are appropriate here. First, consideration of the traditional clinical trial design that has been the focus of attention up until this chapter is extremely worthwhile and instructive It has facilitated the introduction of fundamental design, methodology, and statistical concepts, and it will be an influential player in pharmaceutical drug development for many years to come. Second, the simple observation that the adaptive design may seem different does not in itself make it less valid, less valuable, or less important. Third, statistical approaches that are suitable for adaptive designs are, as yet, less well developed than they are for other study designs. 

Buncher, C.R. and Tsay, J-Y., 2006a, Clinical trial designs. In Buncher, C.R. and Tsay, J-Y., (Eds), Statistics in the pharmaceutical industry, 3rd Edition, Chapman Hall/CRC, 79-90. 

When the patients who received a drug candidate have the disease manifestations completely eradicated and experience no other effects while patients treated with a placebo have a continuation of the disease process, the evaluation is not difficult. However, that is rarely, if ever, the case, and evaluation requires detailed statistical analysis of the collected data. An ICH guide-line covers statistical issues related to the scope of clinical trials, design techniques to minimize bias, types of clinical trial designs, conduct considerations, data analysis for efficacy, evaluation of safety and tolerance, and reporting. 

Unpredictable variability in individual responses, coupled with the need to forecast the aggregate responses of an entire population of future subjects, provide the reasons why biostatisticians are involved in clinical trial design and analysis. Inferential statistics is the discipline of making inferences about populations by analyzing data from samples that were drawn from those populations in a prescribed way. If we could somehow look into a crystal ball and measure the actual future responses to a new drug from the entire... 

Other clinical studies, which include only a few case reports, were all carried out using the extracts of phthalide-containing TCM herbs [364-368]. However, in most of these studies, the general and fundamental clinical trial designs employing features such as randomization, double blinding, placebo control, and proper statistical analysis were rarely employed. 

O Hagan A, Stevens JW, Campbell MJ (2005) Assurance in clinical trial design. Pharmaceutical Statistics 4 186-201. 

Emerson SS (2006) Issues in the use of adaptive clinical trial designs. Statistics in Medicine 25 3270-3296. 

BATAVIA M (2001) Clinical research for health professionals, Boston, Buherworth Heinemarm. CAMPBELL M j, MACHiN D (1999) Medical statistics, New York, John Wiley Sons, Inc. CHOW s c, LIU j p (1998) Design and analysis of clinical trials. New York, John Wiley Sons, Inc. 

The E9 discusses the statistical issues in the design and conduct of a clinical trial. It details trial design, trial conduct, and data analysis and reporting. Although most useful... 

In an optimal world, the CRF is perfectly designed to answer the questions of the study and the clinical data management group will have cleaned the data to perfection. However, to be a good statistical programmer in the clinical trial arena, you must always keep a lookout for errant data and program defensively. Defensive programming lets you account for all possible clinical data permutations. 

Statistics plays a major role in the design of the clinical trial. The groups or subgroups to be studied, the frequencies, dosages, and the markers used to monitor drug efficacy are all important factors to consider. Statistical analysis provides the means to demonstrate, at a certain confidence level, whether the... 

---